Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.42 |
| ▸ | QPCT | Q16769 | 4/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18028285 | 0.77 | FDPS (0.46) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL18216561 | 0.76 | FDPS (0.48) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL10928479 | 0.76 | FDPS (0.49) | FDPSQPCTCYP19A1 | |
| SCHEMBL22710046 | 0.76 | FDPS (0.44) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL25850762 | 0.76 | FDPS (0.44) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL25067251 | 0.76 | FDPS (0.44) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL10999162 | 0.75 | CYP2B6 (0.54) | FDPSQPCTCYP19A1 | |
| SCHEMBL20953982 | 0.75 | FDPS (0.47) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL4581654 | 0.75 | FDPS (0.47) | FDPSTBXAS1QPCTCYP19A1CYP11B1 | |
| SCHEMBL28319514 | 0.74 | TBXAS1 (0.46) | FDPSTBXAS1QPCTCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | FDPS 2341/4885TBXAS1 2858/4885QPCT 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.